This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Ix Biopharma
Ix Biopharma Ltd, headquartered in Singapore (SG), is a pioneering biopharmaceutical company specialising in the development of innovative drug delivery systems. Founded in 2008, Ix Biopharma has made significant strides in the industry, particularly with its proprietary WaferiX™ technology, which enhances the delivery of therapeutics through sublingual administration. The company focuses on pain management and other therapeutic areas, offering unique products that provide rapid onset and improved bioavailability. With a strong commitment to research and development, Ix Biopharma has positioned itself as a leader in the biopharmaceutical sector, achieving notable milestones in product development and regulatory approvals. Its dedication to advancing patient care through innovative solutions underscores its reputation as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Ix Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ix Biopharma's score of 20 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ix Biopharma's reported carbon emissions
In 2023, Ix Biopharma reported Scope 2 emissions of approximately 937,000 kg CO2e. This marks a reduction from 2022, when emissions were about 714,000 kg CO2e, and a decrease from 2021's total of approximately 997,000 kg CO2e. The company has shown a commitment to monitoring and reducing its carbon footprint, although no specific reduction targets or climate pledges have been established. The emissions data is not cascaded from any parent organization, indicating that Ix Biopharma independently reports its emissions. The absence of Scope 1 and Scope 3 emissions data suggests a focus primarily on indirect emissions from purchased electricity, steam, heating, and cooling. As the company continues to assess its environmental impact, further commitments and initiatives may be anticipated in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | - | - | - |
| Scope 2 | 997,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ix Biopharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
